C4 Therapeutics (CCCC) Non-Current Assets (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Non-Current Assets of $83.5 million for Q1 2026, down 4.02% year-over-year from $87.0 million in Q1 2025, and down 17.31% quarter-over-quarter from $101.0 million in Q4 2025.
C4 Therapeutics (CCCC) Non-Current Assets (2019 - 2026) Analysis & Trends
C4 Therapeutics' Non-Current Assets history runs 8 years deep, the most recent figure standing at $83.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 4.02% year-over-year to $83.5 million; the TTM figure through Mar 2026 stood at $314.9 million (down 18.57% YoY), while the FY2025 annual figure was $101.0 million, up 9.94% from the prior year.
- Non-Current Assets for Q1 2026 stood at $83.5 million, down from $101.0 million in the prior quarter.
- The five-year high for Non-Current Assets was $212.5 million in Q1 2022, with the low at $58.6 million in Q3 2025.
- The 5-year median for Non-Current Assets is $105.0 million (2024), against an average of $112.9 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets surged 308.76% in 2022, then slumped 44.68% in 2023.
- C4 Therapeutics' Non-Current Assets stood at $143.3 million in 2022, then declined by 26.54% to $105.3 million in 2023, then declined by 12.76% to $91.8 million in 2024, then climbed by 9.94% to $101.0 million in 2025, then retreated by 17.31% to $83.5 million in 2026.
- Business Quant data shows CCCC's Non-Current Assets at $83.5 million in Q1 2026, $101.0 million in Q4 2025, and $58.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 96.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96.50 Mn |
| Mar 31, 2026 | 83.49 Mn |
| Dec 31, 2025 | 100.97 Mn |
| Sep 30, 2025 | 58.62 Mn |
| Jun 30, 2025 | 71.80 Mn |
| Mar 31, 2025 | 86.99 Mn |
| Dec 31, 2024 | 91.84 Mn |
| Sep 30, 2024 | 102.83 Mn |
| Jun 30, 2024 | 105.05 Mn |
| Mar 31, 2024 | 118.78 Mn |
| Dec 31, 2023 | 105.26 Mn |
| Sep 30, 2023 | 109.33 Mn |
| Jun 30, 2023 | 100.62 Mn |
| Mar 31, 2023 | 117.58 Mn |
| Dec 31, 2022 | 143.28 Mn |
| Sep 30, 2022 | 135.98 Mn |
| Jun 30, 2022 | 174.11 Mn |
| Mar 31, 2022 | 212.54 Mn |
| Dec 31, 2021 | 181.08 Mn |
| Sep 30, 2021 | 95.62 Mn |